Bimagrumab Fights Muscle Loss From Ozempic and Aging

As GLP-1 receptor agonists like semaglutide become mainstream weight-loss therapies, a critical side effect has emerged: up to 40% of lost weight may come from skeletal muscle rather than fat. This accelerates sarcopenia risk — particularly concerning for older adults already vulnerable to muscle loss. Bimagrumab may offer a targeted pharmacological solution to this growing problem.

Bimagrumab is a human monoclonal antibody that blocks activin type II receptors (ActRIIA and ActRIIB), preventing myostatin and related ligands from triggering muscle degradation pathways. By inhibiting this brake on muscle growth, the drug promotes lean mass accrual while simultaneously reducing fat mass — an unusual dual effect among muscle-targeted therapies.

This review from researchers at Weill Cornell and New York Presbyterian synthesizes clinical trial data across several conditions. In sporadic inclusion body myositis, bimagrumab produced meaningful functional improvements in a disease with no previously approved therapy. In sarcopenia and post-hip-fracture recovery, it increased muscle mass, though improvements in strength and mobility were more modest. In obese patients with type 2 diabetes, it reduced fat mass, increased lean body mass, and improved insulin sensitivity.

The combination of bimagrumab with semaglutide is highlighted as particularly promising — preserving muscle while amplifying fat loss. The authors also compare this combination favorably against dual incretin (GLP-1/GIP) therapies and argue for bimagrumab's superiority over competing myostatin inhibitors. Subcutaneous administration now matches IV dosing, improving feasibility.

Caveats include that this is a narrative review without new primary data. Functional outcomes like strength and mobility showed limited improvement despite gains in muscle mass, and long-term safety data remain incomplete. Larger randomized trials combining bimagrumab with GLP-1 agents are still needed.